Insulet (US:PODD)2024-11-08 02:00Financial Performance - Total company revenue reached $543.9 million in Q3 2024, representing a 25.7% increase or 25.4% in constant currency[11] - Total Omnipod revenue grew to $533.6 million, an increase of 26.4% or 26.1% in constant currency[11] - U.S. Omnipod revenue increased by 23.4% to $395.6 million, while International Omnipod revenue grew by 36.1% to $138.0 million[11] - Adjusted gross margin expanded to 69.3% (up 150 basis points), and adjusted operating margin increased to 16.2% (up 350 basis points)[11] Commercial and Strategic Highlights - Over 85% of U.S. New Customer Starts (NCS) transitioned from Multiple Daily Injections (MDI), and over 25% were Type 2 Diabetes patients[17] - Nearly 100% of U.S. volume was distributed through the pharmacy channel[17] - Company celebrated the grand opening of a 400,000 square-foot manufacturing facility in Malaysia[13] Guidance and Outlook - FY 2024 total revenue growth guidance was raised to 20% to 21%, up from the previous range of 16% to 19%[21] - FY 2024 gross margin is projected to be approximately 69%, with the operating margin guidance raised to approximately 14.5%[21]